Treace Medical price target lowered to $5 from $6 at Stifel

Stifel lowered the firm’s price target on Treace Medical (TMCI) to $5 from $6 and keeps a Hold rating on the shares. The company’s Q3 and 2025 guidance update were more complicated than anticipated, as sales did outperform, but management indicated on the call that ta distributor order of roughly $6M made Q3 appear better than the underlying business reality, the analyst tells investors in a research note. The firm noted, however, that CEO John Treace did highlight several factors that support the potential for both more consistent execution and an improved outlook ahead.